Brawn Biotech

Delhi, India Founded: 1986 • Age: 40 yrs Listed
Pharmaceutical formulations are distributed across major healthcare segments.

About Brawn Biotech

Brawn Biotech is a publicly listed company based in Delhi (India) founded in 1986. Pharmaceutical formulations are distributed across major healthcare segments. Its Indian entity Brawn Biotech Limited reported revenue of β‚Ή17.43 Cr. Brawn Biotech offers products and services including Antibacterials, Cardiovasculars, and Antidiabetics. Its focus areas include Pharmaceutical Distributors and Diversified. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.

Company details

Brawn Biotech Ltd. was founded in 1986 and operates as a fully integrated healthcare company based in Delhi, India. Presence is maintained in both domestic and international markets, with pharmaceutical formulations provided across a broad range of product segments. Operations focus on the Indian pharmaceutical industry, where market share is targeted through established distribution networks in the healthcare sector.

  • Headquarters Delhi, India
  • Stage Public
  • Sectors
    Healthcare
  • Website brawnbiotech.com
  • Legal Name Brawn Biotech Limited
Key Metrics
  • Market Cap
    ₹6.30 Cr

    BRAWN · BSE

  • Share Price
    ₹20.99

    -0.05% today

  • Revenue
    ₹16.98 Cr

    FY 2025-26 · +26.2% YoY

  • EBITDA
    −₹0.31 Cr

    Margin -1.8%

  • Net Profit
    ₹0.96 Cr

    FY 2025-26 · +155.2% YoY

  • P/E (TTM)
    31.4x

    P/B 2.0x

  • ROE
    22.2%

    ROCE 0.0%

Products & Services of Brawn Biotech

Brawn Biotech offers a comprehensive portfolio of products and services, including Antibacterials, Cardiovasculars, and Antidiabetics.

Antibacterials
Pharmaceutical Formulations

Medications for treating bacterial infections effectively.

Cardiovasculars
Pharmaceutical Formulations

Drugs for managing heart and blood vessel conditions.

Antidiabetics
Pharmaceutical Formulations

Treatments for controlling blood sugar levels in diabetes.

Board of directors of Brawn Biotech Limited (Brawn Biotech)

Brawn Biotech Limited is the primary company behind Brawn Biotech. The boards of the 2 registered companies of Brawn Biotech currently have 4 directors; the longest-serving is Adarsh Kumar Gupta, appointed in 2003. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Adarsh Kumar Gupta
DIN 00975059
Director02 May 200323 yrs 6 moOverseas Laboratories Private Limited
Brij Raj Gupta
DIN 00974969
Director02 May 200323 yrs 6 moOverseas Laboratories Private Limited, Brawn Biotech Limited
Mayank Jain
DIN 07993851
Director27 Aug 20242 yrs 2 moBrawn Biotech Limited
Pooja Jha
DIN 10749145
Director27 Aug 20242 yrs 2 moBrawn Biotech Limited

IPO & Listings of Brawn Biotech

Brawn Biotech is a publicly listed company on the BSE with ticker symbol BRAWN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 May 1995
  • Listed onBSE: 530207
  • Listed entityBrawn Biotech Limited
  • Exchange sectorHealth technology
  • ISININE899B01015
  • Share price₹23.30 · 2026-10-14
  • Market capitalisation₹7.0 Cr
  • Price to earnings8.1
  • EPS (diluted, trailing year)₹2.86
  • Volume (last session)26

Financials of Brawn Biotech

Exchange-reported figures of Brawn Biotech Limited, the listed company behind Brawn Biotech (BSE: BRAWN).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹16.98 Cr
+26.2% YoY
EBITDA
−₹0.31 Cr
+82.6% YoY
Profit After Tax
₹0.96 Cr
+155.2% YoY
Net Worth
₹4.34 Cr
+29.2% YoY
Total Assets
₹5.69 Cr
-49.0% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Balance sheet
Total assets5.6911.168.086.487.468.979.37
Net worth4.343.365.066.317.228.799.26
Total debt0.000.000.000.000.000.000.00
Cash & bank0.280.200.400.440.220.400.40
Net working capital1.958.186.635.355.867.838.29
Cash flow
Cash from operations0.770.05(0.03)0.320.190.03(0.08)
Cash from investing(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Cash from financing0.000.000.00(0.01)(0.06)(0.04)(0.05)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
Other income0.450.090.090.010.000.310.17
Total expenses17.2915.2417.9622.5210.6235.5748.88
Employee cost0.681.131.401.401.802.363.08
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Depreciation0.120.110.100.110.050.030.03
Interest0.000.000.060.010.060.040.05
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Tax(0.94)(0.06)(0.30)0.45(0.47)0.200.23
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.003.003.003.003.003.003.00
Reserves & surplus1.340.362.063.314.225.796.26
Shareholders' funds (net worth)4.343.365.066.317.228.799.26
Secured loans0.000.000.000.000.000.000.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.000.000.000.000.000.000.00
Total liabilities5.6911.168.086.487.468.979.37
Assets
Gross block1.051.020.780.770.670.380.38
Net block0.360.460.330.370.380.140.18
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories10.0610.476.024.794.720.260.39
Sundry debtors3.553.413.885.322.819.2815.00
Cash & bank balances0.280.200.400.440.220.400.40
Loans & advances3.233.432.842.854.432.793.42
Total current assets17.1217.5113.1413.4012.1812.7319.21
Total current liabilities15.179.336.518.056.324.9010.92
Net working capital1.958.186.635.355.867.838.29
Total assets5.6911.168.086.487.468.979.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.200.000.440.220.400.400.54
Net cash from operating activities0.770.05(0.03)0.320.190.03(0.08)
Net cash from investing activities(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Net cash from financing activities0.000.000.00(0.01)(0.06)(0.04)(0.05)
Net change in cash0.74(0.20)(0.04)0.21(0.17)0.00(0.14)
Closing cash0.280.200.400.440.220.400.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA growth+82.6%-21.1%-406.9%+85.5%-239.0%-179.7%-
PBT growth+9998.0%-16.9%-285.0%+81.0%-502.9%--54.4%
Net income growth+155.2%-41.5%-44.7%+48.2%-198.2%-191.7%-
Revenue CAGR (3Y)-8.6%+16.0%-22.2%-23.5%-49.1%-14.4%-6.4%
EBITDA CAGR (3Y)+2.3%-3.8%+35.6%----15.6%
Profitability & leverage
Net income margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
Return on capital employed0.0%0.0%-20.5%-5.7%-25.0%-3.5%+9.6%
Return on net worth+22.2%0.0%-22.0%-12.9%-20.5%-6.1%+6.6%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.000.00-3.82-2.50-2.93-6.457.04
Efficiency & per share
Fixed asset turnover16.4114.9621.2830.8816.4292.05132.32
Inventory turnover1.651.633.054.683.46107.63135.95
Debtors turnover4.883.693.585.471.432.883.15
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)14.4611.2116.8821.0324.0729.3130.87

Similar companies to Brawn Biotech

Brawn Biotech has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
enterohealthcare.com2018Mumbai, India$59.67M817
India's leading healthcare products distribution platform
keimed.com2000Hyderabad, India$16.62M588
Temperature-sensitive medicines are distributed via cold chain logistics by Keimed.
sandor.co.in1995Hyderabad, India$8.98M161
Provider of medical equipment, devices, and drugs distribution services
Premium access

Detailed similar companies of Brawn Biotech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Brawn Biotech

The website of Brawn Biotech (brawnbiotech.com) receives about 1.5K visits a month.

  • Monthly visits
    1.5K

    ▲ 22.1% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Brawn Biotech

Premium access

Complete news archive for Brawn Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Brawn Biotech

Brawn Biotech was founded in 1986.

Brawn Biotech is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

The primary company behind Brawn Biotech, Brawn Biotech Limited, reported revenue of β‚Ή17.43 Cr for FY 2026, up 26% year on year.

Brawn Biotech Ltd. was founded in 1986 and operates as a fully integrated healthcare company based in Delhi, India. Presence is maintained in both domestic and international markets, with pharmaceutical formulations provided across a broad range of product segments. Operations focus on the Indian pharmaceutical industry, where market share is targeted through established distribution networks in the healthcare sector.

Brawn Biotech's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.

Brawn Biotech offers Antibacterials, Cardiovasculars, and Antidiabetics.

Yes, Brawn Biotech is publicly traded on BSE under the ticker symbol BRAWN.

Brawn Biotech is associated with 2 legal entities: Brawn Biotech Limited, Overseas Laboratories Private Limited.

The legal entities of Brawn Biotech currently have 6 directors, including Adarsh Kumar Gupta, Brij Raj Gupta, Priyanka Sharma and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available